Home » Newsletters » BioWorld Science

BioWorld Science

May 27, 2004

View Archived Issues

Oral combination approaches with VX-950, VX-497 for HCV treatment; VX-950 comparable to BILN-2061

Comparison of the efficacy of tenatoprazole and esomeprazole in inducing gastric acid suppression

OPC-6535 shows promise in the treatment of ulcerative colitis

Preclinical report on MDI-P in mouse model of cystic fibrosis

Roche will not opt in for Basilea's BAL-5788

Spiriva HandiHaler available in U.S.

Oral MNTX formulations complete phase I trials

Idex acquires Scivex

Allergan and Senju sign Japanese licensing agreement for Lumigan

Fast track designation for INO-1001

Enrollment completed in STELLAR 4 trial of Xyotax

NDA filing for Xibrom

DX-88 development placed on hold pending preclinical review

Schering-Plough reviews option for intranasal pleconaril

Juvaris enters licensing agreement for new therapeutic vaccine platform

Xanafide enters phase I/II study for metastatic prostate cancer

R-115777 active but poorly tolerated in MDS; does not prolong survival with gemcitabine

Vertex plans METRO study for merimepodib

Liraglutide shows promise in type 2 diabetes

Pexelizumab reduces events in patients undergoing CABG

Enrollment completed in ADHD phase II study of NS-2359

Benefits associated with IB-MECA in a model of experimental colitis

Selective calcium channel inhibitor blocks hyperalgesia effectively in vivo

Roche presents pegylated IGFBP-4 conjugates and their use in cancer therapy

Arena develops antilipolytic agents targeting the nicotinic acid RUP25 receptor

New adenosine A2A antagonists for PD, depression, dementia, etc.

Novel antitumor podophyllotoxins developed by Plantaceutica researchers

Aventis claims glucose lowering agents for type 2 diabetes and other disorders

New anti-herpes virus agents discovered by GSK team